English
Arabic
Chinese (Simplified)
Dutch
Esperanto
French
German
Greek
Italian
Japanese
Korean
Portuguese
Russian
Spanish
UrduNew smart-drug treatment options for pancreatic cancer, immuno-oncology treatments and real-time immune-monitoring strategies are among the research topics to be presented by investigators at The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC – James) at the American Association for Cancer Research (AACR) annual meeting held April 14-19 at the Orange County Convention Center in Orlando, Florida.
Tag: precision cancer medicine
Pralsetinib achieves tissue-agnostic benefits for patients with RET gene fusions
The targeted therapy pralsetinib was well-tolerated and demonstrated high response rates in patients with RET gene fusions regardless of tumor type, according to results from the Phase I/II ARROW trial.